Effects of histone deacetylase inhibitors on rat mesangial cells

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 2, 2010, Pages

  Freidkin, Ilya ^a   Herman, Michal ^a,c   Tobar, Ana ^b,c   Chagnac, Avry ^a,c   Ori, Yaacov ^a,c   Korzets, Asher ^a,c   Gafter, Uzi ^a,c  

^a HASHARON HOSPITAL   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Collagen IV; Mesangial cells; Proliferation; Smooth muscle actin; Trichostatin A; Valproic acid

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE INHIBITOR; SCLEROPROTEIN; THY 1 ANTIGEN; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; GLOMERULOSCLEROSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN SYNTHESIS; PROTEINURIA; RAT;

EID: 75149128159     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00107.2009     Document Type: Article

References (52)

1. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278: 28930-28937, 2003.
2. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320, 1998.
3. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
4. Elger M, Drenckhahn D, Nobiling R, Mundel P, Kriz W. Cultured rat mesangial cells contain smooth muscle α-actin not found in vivo. Am J Pathol 142: 497-509, 1993.
5. Eng E, Floege J, Young BA, Couser WG, Johnson RJ. Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? Kidney Int Suppl 45: S45-S47, 1994.
6. Gilbert SF, Migeon BR. D-Valine as a selective agent for normal human and rodent epithelial cells in culture. Cell 5: 11-17, 1975.
7. Haas CS, Schocklmann HO, Lang S, Kralewski M, Sterzel RB. Regulatory mechanism in glomerular mesangial cell proliferation. J Nephrol 12: 405-415, 1999.
8. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121, 2005.
9. Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int 66: 187-195, 2004.
10. Higuchi M, Aggarwal BB. Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation, and differentiation. J Immunol 152: 4017-4025, 1994.
11. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005.
12. Ishimura E, Sterzel RB, Budde K, Kashgarian M. Formation of extracellular matrix by cultured rat mesangial cells. Am J Pathol 134: 843-855, 1989.
13. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175: 1413-1416, 1992.
14. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int 45: 1769-1782, 1994.
15. Kalechman Y, Sredni B, Weinstein T, Freidkin I, Tobar A, Albeck M, Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. J Am Soc Nephrol 14: 620-630, 2003.
16. Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albeck M, Sredni B. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis: association with dephosphorylation of STAT3. J Biol Chem 279: 24724-24732, 2004.
17. Kaname S, Uchida S, Ogata E, Kurokawa K. Autocrine secretion of transforming growth factor-β in cultured rat mesangial cells. Kidney Int 42: 1319-1327, 1992.
18. Kitamura M, Burton S, English J, Kawachi H, Fine LG. Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int 48: 1747-1757, 1995.
19. Lee HB, Noh H, Seo JY, Yu MR, Ha H. Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int Suppl 72: S61-S66, 2007.
20. Lei J, Silbiger S, Ziyadeh FN, Neugarten J. Serum-stimulated α1 type IV collagen gene transcription is mediated by TGF-β and inhibited by estradiol. Am J Physiol Renal Physiol 274: F252-F258, 1998.
21. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
22. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2: 325-332, 2002.
23. Marshall CB, Shankland SJ. Cell cycle and glomerular disease: a minireview. Nephron Exp Nephrol 102: e39-e48, 2006.
24. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552, 2003.
25. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valporic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979-1985, 2007.
26. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867, 1999.
27. Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, Ishikawa Y, Yokoyama M. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb 13: 183-191, 2006.
28. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, Takahashi T. Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61: 8331-8339, 2001.
29. Papeleu P, Loyer P, Vanhaecke T, Elaut G, Geerts A, Guguen-Guillouzo C, Rogiers V. Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogenstimulated rat hepatocytes. J Hepatol 39: 374-382, 2003.
30. Papeleu P, Vanhaecke T, Elaut G, Vinken M, Henkens T, Snykers S, Rogiers V. Differential effects of histone deacetylase inhibitors in tumor and normal cells - what is the toxicological relevance? Crit Rev Toxicol 35: 363-378, 2005.
31. Poncelet AC, Schnaper HW. Regulation of human mesangial cell collagen expression by transforming growth factor-β1. Am J Physiol Renal Physiol 275: F458-F466, 1998.
32. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 277: C1-C9, 1999.
33. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 2069-2083, 2000.
34. Rangan GK, Tesch GH. Quantification of renal pathology by image analysis. Nephrology 12: 553-558, 2007.
35. Razzaque MS, Ahsan N, Taguchi T. Role of apoptosis in fibrogenesis. Nephron 90: 365-372, 2002.
36. Reilly CM, Thomas M, Gogal R Jr, Olgun S, Santo A, Sodhi R, Samy ET, Peng SL, Gilkeson GS, Mishra N. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 31: 123-130, 2008.
37. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, NolÈ F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 100: 28-36, 2009.
38. Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A. Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg 64: 239-46, 2001.
39. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K, De Bleser P, Yoshida M, Schuppan D, Rojkind M, Geerts A. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-β1-induced fibrogenesis in skin fibroblasts. Exp Cell Res 278: 184-197, 2002.
40. Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, Hellemans K, De Bleser P, Gelman I, Ramadori G, Geerts A. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 37: 788-796, 2002.
41. Sedor JR, Konieczkowski M, Huang S, Gronich JH, Nakazato Y, Gordon G, King CH. Cytokines, mesangial cell activation and glomerular injury. Kidney Int Suppl 39: S65-S70, 1993.
42. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottière HM. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46: 507-514, 2000.
43. Simonsson M, Heldin CH, Ericsson J, Grönroos E. The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 280: 21797-21803, 2005.
44. Stephenson LA, Haney LB, Hussaini IM, Karns LR, Glass WF 2nd. Regulation of smooth muscle α-actin expression and hypertrophy in cultured mesangial cells. Kidney Int 54: 1175-1187, 1998.
45. Striker LJ, Doi T, Elliot S, Striker GE. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 9: 318-328, 1989.
46. Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, Taiji M. SMP-534 inhibits TGF-β-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 289: F998-F1004, 2005.
47. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
48. Wahab NA, Mason RM. A critical look at growth factors and epithelialto-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 104: e129-e134, 2006.
49. Wetzel M, Premkumar DR, Arnold B, Pollack IF. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J Neurosurg 103, Suppl 6: 549-556, 2005.
50. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucoseinduced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 42: 647-656, 1992.
51. Yoo EJ, Chung JJ, Choe SS, Kim KH, Kim JB. Down-regulation of histone deacetylases stimulates adipocyte differentiation. J Biol Chem 281: 6608-6615, 2006.
52. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007.